Information For Authors
- Manuscript Submission Guidelines
- Author Benefits Program
- Open Access Policy
- NIH/HHMI Wellcome Trust Policies
- Self-Archiving Policy
AIMS & SCOPE
The CRISPR Journal is the indispensable journal for CRISPR biology, technology and gene editing, published by Mary Ann Liebert, Inc. publishers. The journal will be the voice of the international CRISPR community, publishing groundbreaking research and vigorous discussion and commentary. The journal’s Editor-in-Chief is Professor Rodolphe Barrangou, and the Executive Editor is Dr. Kevin Davies; it has a talented quartet of associate editors and a distinguished international editorial board. The journal strives to treat authors fairly and considerately; it aims to publish important work of general interest to the community without imposing fussy experimental requirements on authors.
All manuscripts must be submitted through our online peer review sitea:
***Please read all instructions below before proceeding.***
aCreate an Account in Manuscript Central
Submissions to The CRISPR Journal are managed through our online peer review system, Manuscript Central. If you do not already have an account in Manuscript Central specifically for The CRISPR Journal, you will need to create one. Once you create your account, you may log in to the system to begin your submission . Each listed author on a submission must either already have an account, or have one created, in the system. Before creating an account for your coauthor(s), search the database using your coauthors' email addresses to ascertain if an account already exists. If no account exists, you may create one on behalf of your coauthor(s). For technical assistance, contact AuthorServices@liebertpub.com
Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, in the same form or substantially similar form, except in the form of an abstract.
The CRISPR Journal recognizes the growing popularity of community non-peer-reviewed preprint repositories such as bioRxiv, arXiv, ChemRxiv, PeerJ Preprints, etc. Deposition of a preprint on a preprint server will not impact consideration of any manuscript submitted to The CRISPR Journal. The existence of a publicly available preprint should be declared upon submission.
USE OF ENGLISH LANGUAGE
All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in The CRISPR Journal. For authors whose native language is not English, we recommend using a service that will aid in the translation and rewriting of material into correct and proper English usage. The Publisher offers this service for a fee prior to official submission. For more information, please contact: Editing@liebertpub.com Please note that employing the use of the Publisher's service is not required, and using it does not guarantee acceptance of any paper. All submissions are subject to peer review.
MANUSCRIPT TYPES AND WORD LIMITS
Word limits do not include the title, abstract, authors and affiliations, keywords, figure legends, tables, acknowledgements, authorship confirmation statement, author disclosure statements, acknowledgments, or references. Exceptions to the limitations set herein are permissible at the discretion of the Editor(s).
|Review Articles||5,000 word limit, 150 references, and a total of 10 figures and tables|
|Original Articles||3,000 word limit, 100 references, and a total of 10 figures and tables|
||1,000 word limit, 2 figures/tables|
|Commentaries||2,500 word limit|
|Editorials||1,000 word limit|
|Correspondence||800 word limit, 10 references and 1 table OR figure|
Keywords (Areas of Expertise to be used for peer review)
While uploading your manuscript files, you will be asked to select 4-6 keywords from the drop-down list of pre-selected terms to facilitate the peer review process. These keywords will assist in the selection of skilled reviewers in the field for the purposes of peer review.
PRESENTATION OF MANUSCRIPT (Please follow these requirements and sequence:)
A title page of your submission must be included as part of your main text document (not as a separate file) and must include the following items:
- The complete title of the article;
- All contributing authors' full names, complete affiliation and mailing address, full contact information (telephone and e-mail address );
- A brief running title of no more than 45 characters, including spaces;
- Denotation of the corresponding author and his/her complete contact information including address and email address;
- Three (3) to six (6) manuscript keywords.c
Create an Effective Title:
- Manuscript titles should be brief, contain key terms, and clearly identify the purpose of the work conducted
- Titles should be no more than 12-15 words
- Titles should be direct and to the point. Remember that the journal has a global readership, so clear and concise non-vernacular language is most effective
- Avoid the use of specific locations in the title
- Do not use proprietary/trademarked names in the title
- Do not use acronyms in the title unless they are universally recognized and accepted
Authorship Confirmation Statement
On a separate page within the manuscript file, following the title page, include a paragraph detailing each listed authors' contributions to and responsibilities for the manuscript. This text should also contain a statement that all co-authors have reviewed and approved of the manuscript prior to submission. Lastly, include a confirmation statement that the manuscript has been submitted solely to this journal and is not published, in press, or submitted elsewhere (posting on a non-peer-reviewed preprint server does not constitute prior publication).
Author Disclosure Statementsd
On a separate page within the manuscript file, following the Authorship Confirmation Statement page, include any financial conflicts of interest, actual or potential, for each listed author on the submission. If no conflicts exist, the authors must state, "No competing financial interests exist." Articles submitted without Author Disclosure Statements will be un-submitted so that a statement may be added.
dSee the JOURNAL POLICIES section below for more information, or visit the ICJME website at www.icmje.org
- The abstract must be in Word and included in the main text file, after the Author Confirmation Statement.
- Prepare abstract on a separate page to be included after the title page and the Authorship Confirmation Statement page
- Abstract should be unstructured. (Abstract does NOT need Background, Materials & Methods, Results, and Conclusions sections identified)
- The abstract should briefly summarize the background and rationale of the study, and clearly summarize the results and conclusions of the work
- Abstract should be no more than 150 words.
- References are not permitted in the abstract
- Do not use proprietary or trade names in the abstract
- Name all files in English and use only alphanumeric characters. Do not use symbols, dots, lines, or dashes.
- Figure files names should be formatted with first author's last name and the figure number. (Ex: SmithFig1)
Main Text File:
After the title page, abstract, Authorship Confirmation, and Author Disclosure Statements, prepare the remainder of the text following this sequence of sections:
- Materials and Methods
- Appendices (if applicable)
- Prepare each figure as individual .TIFF or .EPS file
- Do NOT submit figures in Word, PowerPoint, PDF, Bitmap, .JPEG, or Excel.
- Line illustrations must be submitted at 900 DPI.
- Halftones and color should be submitted at a minimum of 300 dpi.
- Color art must be saved as CMYK - not RGB. (N.B., If RGB files are submitted, the files will be converted to CYMK and some color variation will occur.)
- Black and white art must be submitted as grayscale – not RGB.
Additional Information on Converting Figure Files
Converting Word or Excel files: The best and easiest way to convert Word or Excel files into a format which is suitable for print is to scan them using the below guidelines:
- All files should be scanned at 100% size
- At least 300 dpi
- Final color mode: CMYK
- Save file as: .tif, .tiff, or .eps
For more direction on how to convert a Power Point slide to acceptable format go to: www.liebertpub.com/MEDIA/pdf/ppconvert.pdf
Color Publication Costs: See Journal Fees section below.
- Prepare and save each table in individual .doc or .docx files.
- Do not include tables in the main manuscript text file.
- Do not embed tables within the text.
- Include a table number and a title for each supplied table.
- Use Arabic numerals to number tables.
- Do not repeat information that is given in the text, and do not make a table for data that can be given in the text in one or two sentences.
- Define all acronyms used within the body of the table in table footnotes.
- All other types of table footnotes should be designated using superscript letters, not symbols.
- Name all table files in English and use only alphanumeric characters. Do not use symbols, dots, lines, or dashes.
- Table file names should be formatted with first author's last name and the figure number. (Ex: SmithTable1)
- Upload individual table file under the "Table" file designation.
When appropriate, we encourage the judicious use of online-only supplementary information (SI). All information/data in the SI should be referred to in the article text, including reference to specific tables and figures in the SI. Upload supplementary tables, figures, and legends as separate files, either as "supplementary file" or "supplementary file for review only." The manuscript should be written so that the paper which appears in the printed journal contains all data which are key to the conclusions and important for the reader to have direct access to when reading the paper. Other supporting data and text are appropriate for the supplementary section.
Order of Files During Submission
Upload manuscript files to our system in the following order:
- Manuscript/Main text file
- Figure Legends
- Supplementary files
Note: There is a total limit of 200 MB per submission.
Reference List Preparation. Prepare a numbered (not alphabetical) reference list, in the order of citation within text and double spaced, at the end of the text of the manuscript (do not upload the reference list as a separate file). See formatting examples below.
In-Text Citations. Cite all references appearing in the reference list in numerical order, as superscripted numbers (no parentheses) and outside sentence punctuation.
If more than three authors are listed on an article, list the first three authors then use et al. (not italic) after the third author's name. Abbreviations of journal titles in reference section should follow the style of MEDLINE (http://www.ncbi.nlm.nih.gov/nlmcatalog). If a work is in press, state the journal title in which it is to be published, and include "in press" in parenthesis in place of a volume and page range. When references to unpublished sources/correspondence are used, supply the researcher's name and date.
For Users of EndNote:
Download the output style for The CRISPR Journal at: http://endnote.com/downloads/style/crispr-journal
[The CRISPR Journal requires DOIs journal article references (see sample below), after the page range.]
NOTE: The publisher of The CRISPR Journal does not provide technical support for EndNote. If you have questions, click on the Support tab on EndNote's website for assistance.
Sontheimer EJ, Barrangou R. The bacterial origins of the CRISPR genome-editing revolution. Hum Gene Ther. 2015;26:413-424. DOI: 10.1089/hum.2015.091
Watson JD, Berry A, and Davies K. DNA: The Story of the Genetics Revolution. New York, NY: Knopf. 2017.
Chapter in a Book:
Hawkins JS. Targeted transcriptional repression in bacteria using CRISPR interference (CRISPRi) In: CRISPR: Methods and Protocols. (Lundgren M, Charpentier E, Fineran PC; eds). Springer, New York, NY. 2015; pp. 349–362.
Website: Please follow this structure for website references, including capitalization and punctuation:
List author (if available) and/or page name/title. Website article title. Provide website URL. Include last accessed date.
Conference Proceedings: Please follow this structure for Conference Proceeding references, including capitalization and punctuation:
List all Authors' (or) Editors' names (last name first, followed by first and middle initials). Conference title. Date of conference. Location of conference. City of publisher: Publisher; Year of publication. Complete number of pages in proceedings book.
Preprint: Preprints may be cited in same manner as a journal article; discretion is recommended as preprints are by definition not peer-reviewed.
Do NOT create a new submission for revisions of already-submitted manuscripts. Detailed instructions for submitting revised manuscripts are provided in an email which is sent to the corresponding author along with the reviewers' comments. Revised submissions routinely will undergo further review by the same reviewers who assessed the original submission, members of the editorial board, and/or the editor(s). Contact the Editorial Office immediately if the deadline for your revised submission has expired. Please note that an invitation to revise any submission does not guarantee acceptance.
COPYRIGHT AGREEMENT FORM
Upon acceptance of any manuscript, all authors will receive an email with detailed instructions and a unique, author-specific link to access and complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors' email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications. FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM WILL RESULT IN A DELAY OF PUBLICATION. The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright. Copyright forms may also be completed by logging in to the system using an author's credentials. After logging on, click on Author Center and complete the forms located under "Manuscripts I Have Coauthored."
Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc., unless alternate arrangements are made prior to publication, including CC-BY licensing (see below). By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal.
OPEN ACCESS / CC-BY LICENSING
The CRISPR Journal is a subscription-based peer-reviewed journal with Open Access options. Creative Commons CC-BY and CC-BY-NC licensing is available for all articles published open access for a standard Article Processing Charge (APC) of $3,200.00 USD. Please contact our Open Access Manager to order open access for your article. For more information about open access publishing, please visit our Liebert Open Access website.
When reproducing copyrighted material such as figures or tables, the author(s) must obtain permission from the original publisher and submit it concurrently with the manuscript. Written permission must be obtained from the copyright holder/publisher of the material concerned. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote to a reprinted table or the legend of a reprinted figure should read, "Reprinted by permission from Jones et al." and list the appropriate reference. All permissions must be supplied at the time of submission. Authors are responsible for any fees that may be incurred by securing permission to reproduce or adapt material from other published sources.
POST-ACCEPTANCE / PRODUCTION
All accepted manuscripts will go through copyediting, typesetting, figure sizing and placement, author proofing, corrections, revisions (from corrected proofs), online-ahead-of-print release, and lastly, issue assignment. Depending on the length and complexity of any accepted submission, these steps typically take 3-6 weeks from acceptance.
Page proofs will be sent to the (one) corresponding author as designated when the manuscript was submitted. It is the corresponding author's responsibility to share the page proofs with co-authors and to coordinate all authors' corrections into one proof. The Publisher will not accept corrections from multiple authors.
AUTHOR RESPONSE TO GALLEY PROOF
The corresponding author is responsible for returning corrected galley proofs within 72 hours of receipt. Only corrections directly related to errors in typesetting will be allowed. Other changes will have to be approved by the Editor. If the corresponding author does not respond within that time, the manuscript may be delayed in the publication schedule, or published as is, at the discretion of the Editor and Publisher. If the corresponding author expects to be unavailable during the time the manuscript is in production, the publisher should be provided with an alternate contact.
Reprints may be ordered by following the special instructions that will accompany the proofs, and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.
The CRISPR Journal generally follows Committee on Publication Ethics (COPE; https://publicationethics.org/ and International Committee of Journal Medical Editors (ICJME; http://www.icmje.org/) guidelines.
The CRISPR Journal is a single-blinded peer-reviewed journal. All submissions are subject to peer review. A minimum of two expert reviewers in the area of study will be selected to assess the scientific basis and significance of the manuscript. Following peer review, the Editor and/or Associate Editors will determine if the paper should be accepted, require revision, or is unacceptable for publication.
Time in Review: The journal strives to maintain a short, but thorough peer-review process. The average time in review is 21 days but the Editor will strive to expedite manuscript handling if circumstances dictate.
Editors and reviewers must maintain strict confidentiality of manuscripts during the peer-review process. Sharing a manuscript in whole or in part, outside the scope of what is necessary for assessment, is impermissible prior to the manuscript's official publication date.
Sharing of Materials Policy
Authors must honor any reasonable request for materials, methods, or data necessary to reproduce or validate the research findings during peer review , unless it violates the privacy or confidentiality of human research subjects .
Papers Authored by the Editor-in-Chief and/or Associate Editors
The Editor-in-Chief and Associate Editors will recuse themselves from participating in the review process of any manuscript in which there is a potential or actual competing interest.
Internal Review Board Approvals/Waivers (as described and defined on the World Medical Association's website; www.wma.net
When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.
If the study is judged exempt from review, a statement from the committee should be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and a sentence declaring adherence should be included in the acknowledgment section of the manuscript.
STUDY DESIGN AND ETHICS
If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images of patients. The Journal does not provide a generic patient release form.
Any identifying information should not be published in descriptions or photographs unless the information is essential for scientific purposes and the patient (or parent/guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be submitted. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication.]] Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, the manuscript should contain assurances/statements that such changes do not distort scientific meaning.
In keeping with patients' rights of privacy, the Journal does not require the submission of patient consent forms, but instead requires the author(s) to retain and archive all patient consent documentation. Upon submission of a manuscript for review, the authors must make a statement in a cover letter to the Editor/Journal which attests they have received and archived written patient consent.
ETHICS OF EXPERIMENTATION
All articles involving the use of human fetuses, fetal tissue, embryos, and embryonic cells must adhere to the US Public Law 103–41, effective December 13, 2001. (http://ethics.od.nih.gov/.)
Ethical Treatment of Animals
All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles, and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.
All authors are encouraged to complete their submissions using an ORCID identifier . Please visit the ORCID website for more information, or to register.
There is no limit of authors permitted on a single submission , but in cases where there are 20 or more co-authors, The CRISPR Journal recommends that a collective group or consortium name be provided and the individual authors listed in the Acknowledgements.
Definition of Authorship
Authorship, as defined by the International Committee of Medical Journal Editors, is based on the following criteria1:
- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
- Drafting the work or revising it critically for important intellectual content; AND
- Final approval of the version to be published; AND
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
It is the Journal's policy that a manuscript has only ONE corresponding author listed on a paper. This designation should be determined at the time of submission. All communications regarding any submission, except for copyright forms, will be directed only to the corresponding author.
Working Groups/Team Authorship
Working Groups or Teams may be listed in the manuscript byline, but the entire listing of names should be included in the acknowledgment section of the manuscript. Do not list the names in a footnote on the title page.
Variations of Authorship
It is permissible to list up to three authors as co-first authors. Include an asterisk (*) next to the authors' names who are considered as first authors. Include a corresponding footnote, using the asterisk, on the title page that reads, "These authors contributed equally to this work and are considered to be co-first authors."
Contributors who meet fewer than all four of the above criteria for authorship should not be listed as authors, but they should be acknowledged.
Changes in Authorship
Changes in authorship after acceptance are discouraged, but the editorial leadership recognizes that in certain circumstances, it is required. The journal's policy is as follows:
- A request to alter authorship must be made in writing from the corresponding author to the Editor-in-Chief, with a detailed explanation for the request, and the names and affiliations of the authors requiring addition and/or deletion.
- Authorship may be altered after acceptance of a paper with the written approval of all authors named on the manuscript, as well as the individual(s) being added and/or deleted. The Publisher can provide a form for this, if needed.
- Upon receipt of the request and all written approvals of all involved parties, the Editor-in-Chief will consider the request, render a decision, and notify the corresponding author.
- There is a one-year post-publication statute of limitation on requests for alterations in authorship.
***Important Note about Author Listing***
It is incumbent upon the submitting author to ensure the accuracy and inclusion of all contributing authors' names and affiliations upon original submission of the paper. All authors' names must be entered into the Journal's submission site.
AUTHOR DISCLOSURE STATEMENTS
1. Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
2. Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
3. Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
4. Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
5. Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.
SELF-CITATION AND SELF-PLAGIARISM
The CRISPR Journalis committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. All manuscripts will be processed through plagiarism detection software prior to acceptance. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content compared to work previously published by authors, self-plagiarism can infringe upon a publisher's copyright. To avoid plagiarism, be sure to cite all published works.
- There are no submission fees to the Journal.
- There no page charges for the Journal.
- The CRISPR Journal is currently waiving fees for color printing.
- Open Access and Creative Commons licensing options are available. Contact our Open Access Manager for more information.
- For pricing and purchasing reprints, contact our Reprints Manager.
RESEARCH FUNDER COMPLIANCE (FundRef)
Upon submission of a manuscript, you will have an opportunity to enter funding/grant information. If funding information is entered correctly, the publisher will deposit the funding acknowledgements from the article as part of the standard metadata. The entered information should include funder names, funder IDs (if available), and associated grant numbers. (See https://www.crossref.org/services/funder-registry/ for a listing of more than 13,000 international funding agencies.)
GOVERNMENT FUNDED RESEARCH
The CRISPR Journal is fully NIH-, HHMI-, RUCK, and Wellcome Trust-compliant.
Our open access publishing solutions allow you to comply with the open access policies of your institution, government, and funding body. If you are employed or funded by the National Institute of Health (NIH), the Wellcome Trust, Research Councils UK (RCUK) or Howard Hughes Medical Institute (HHMI), you can find more information below:
Wellcome Trust Policy– To easily comply, you can choose to have your article published open access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the Wellcome Trust.
Research Councils UK (RUCK) – To easily comply, you can choose to have your article published Open Access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the RUCK.
HHMI and NIH Public Access Policy– In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final paginated version of the published article to PubMed Central (PMC) on behalf of the authors after a 12-month embargo period. Authors need not take any action. This service is provided free of charge. Authors who wish to remove the 12-month embargo period are encouraged to consider publishing with Open Option.
RESPONDING TO ALLEGATIONS OF POSSIBLE MISCONDUCT
The Publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of the Journal who in turn will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals, or if the allegation is against an editor, an outside expert. The Editor-In-Chief will arrive at a conclusion as to whether there is enough reasonable evidence that the possibility of misconduct occurred.
When allegations concern authors, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.
Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with the Journal, and reported to their institution.
If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will retract the paper from the Journal and the scientific record. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.
All allegations will be kept confidential.
DEFINITIONS OF SCIENTIFIC MISCONDUCT
Mary Ann Liebert, Inc., publishers generally follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).
Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:
- Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
- Authorship Disputes: Deliberate misrepresentation of a scientist's contribution to the published work, or purposefully omitting the contributions of a scientist.
- Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
- Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
- Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
- Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
- Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
- Plagiarism: Purposely claiming another's work or idea as your own constitutes misconduct and/or fraud.
- Simultaneous Submission: Submitting a paper to more than one publication at the same time constitutes misconduct.
ARCHIVING AND PRESERVATION
Mary Ann Liebert, Inc., deposits and archives all publications in Portico for long-term digital preservation. Your article will be easily searchable on Google, Google Scholar, and other search engines.
In the event an error is discovered after publication of an article, the corresponding author should submit the correction in writing to the editorial office for consideration. Changes in author affiliations or contact details due to relocation are not permitted after publication.
Corrections to meeting abstracts will be made only to the online version. The Journal does not issue formal correction statements for corrections to meeting abstracts, regardless of the nature of the correction.
The CRISPR Journal is owned by Mary Ann Liebert, Inc., publishers, 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801; Tel: 914-740-2100; Email: Info@liebertpub.com; Website: www.liebertpub.com/CRISPR
Our dynamic Author Benefits Program provides you with end-to-end benefits that ensure your hard work pays off and your published manuscript gets the attention it deserves not just upon publication, but permanently.
Ensure maximum visibility, discoverability, and impact for your article with our Liebert Open Access (OA) option
Does your research funder have an open access mandate or would you like to expand the dissemination of your research?
The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.
The benefits of Liebert Open Access include:
- High visibility; open access articles are freely available online upon publication
- You retain copyright with the open access license allowing broad dissemination of your research
- You can freely share your article in repositories and research networks without restrictions
- Easy compliance with open access mandates
- Rigorous editorial and peer-review
- Targeted email announcement featuring a direct link to article
Identification and Marketing
Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.
Copyright and Licensing
If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
Ordering Open Access
Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email firstname.lastname@example.org.
Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.
Publishing biomedical or biotechnology research?
Biomedical researchers should consider publishing in BioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.
*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.
Browse journals in the Liebert Open Access portfolio:
NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.
Publishing in Subscription Journals
By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.
Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.
The final published article (version of record) can never be archived in a repository, preprint server, or research network.
Publishing Open Access
Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Access option allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email email@example.com or visit Liebert Open Access for more information.